SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com/.
Revolutions Medical Corporation (OTCBB: RMCP) $0.49. Announced Monday after market close detailed performance and aesthetic improvements to its flagship Rev Vac syringe, and debuted a highly informative product demonstration video.
"We will unveil the long-anticipated enhanced design of the Rev Vac safety syringe on our website tonight," stated Company CEO Ron Wheet. "The improvements increase substantially the readability of the fluid levels and the accuracy of the fluid draw. A distinctive color scheme makes the Rev Vac syringe easily identifiable. Simple to read pictograms on each packet insert allow for reduced training needs while improving correct usage. Combined, these feature enhancements dramatically escalate our competitive advantage in the space, and ensure a product that not only costs less, but significantly outperforms many established products.
"And with our new animated demonstration video, we now have an engaging and educational resource that will serve as both an exceptional sales piece and an unparalleled training tool. At time of product launch, we will feature a dynamic multi-media marketing platform that will further set Revolutions Medical apart as the leading safety syringe company."
The Rev Vac safety syringe received FDA 510K clearance earlier this year; this redesign does not impact that clearance.
What They Do: Revolution Medical's products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D and automatic segmentation of images.
Cell Therapeutics (Nasdaq: CTIC) $1.37. Today announced that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in
"PIPs were introduced by the European Commission to help ensure that medicines that may have benefit in pediatric indications are evaluated in children," said Jack Singer, CTI's Chief Medical Officer. "Anthracyclines are a mainstay in the treatment of childhood leukemias, lymphomas and solid tumors but long-term cardiotoxicity represents a significant issue. We are planning to evaluate safety and efficacy of pixantrone in pediatric cancer patients."
CTI recently received a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 in the
What They Do: Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.
Lexicon Pharmaceuticals (Nasdaq: : LXRX) $1.62. Today announced it has obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes meelitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon's fourth drug candidate currently being tested in Phase 2 clinical trials.
What They Do: Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.
SulphCo (Amex: SUF) $1.75. Today announced it has entered into a letter of intent (the "LOI") with Laguna Development Corporation ("Laguna") to move toward the commercial installation of SulphCo's desulfurization technology.
Under the terms of the LOI, Laguna has agreed to evaluate SulphCo's Sonocracking(TM) technology to reduce the sulfur content of the diesel stream produced at Laguna's
What They Do: SulphCo has developed a patented safe and economic process employing ultrasound technology to alter the molecular structure of crude oil and crude oil products.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/. SCR has been compensated up to three thousand five hundred dollars by a third party APS for its services with regards to Revolutions Medical Corporation.
